Published in final edited form as:

Tetrahedron Lett. 2016 September 7; 57(36): 4056–4060. doi:10.1016/j.tetlet.2016.07.082.

Rapid, Microwave Accelerated Synthesis of [1,2,4]Triazolo[3,4-*b*][1,3,4]oxadiazoles from 4-Acylamino-1,2,4-Triazoles

Stesphanie L. Breunig, Margaret E. Olson, and Daniel A. Harki*

Department of Medicinal Chemistry, University of Minnesota, Minneapolis, MN, 55455, USA

Abstract

1,2,4-Triazoles and 1,3,4-oxadiazoles are prevalent moieties in pharmaceutical agents, yet fused [1,2,4]-triazolo[3,4-*b*][1,3,4]oxadiazoles are surprisingly under-represented for both synthesis and biological application. We report a rapid, two-step synthesis of [1,2,4]-triazolo[3,4-*b*][1,3,4]oxadiazoles from commercial 4-amino-1,2,4-triazoles that is highlighted by a microwave accelerated intramolecular cyclization to generate the fused ring system. Our efforts to optimize reaction conditions and elucidate reaction mechanism are also described.

Graphical abstract

Keywords

1,2,4-Triazole; 1,3,4-Oxadiazole; [1,2,4]Triazolo[3,4-*b*][1,3,4]oxadiazole; Microwave Chemistry; Intramolecular Cyclization

Introduction

1,2,4-Triazoles are represented in diverse molecules with antimicrobial,¹⁻² antitubercular,³ anticancer,⁴ analgesic,⁵ and anticonvulsant⁶ activities. Notably, the antiviral drug ribavirin and antifungal drugs fluconazole, itraconazole, and voriconazole possess a 1,2,4-triazole. In a similar vein, 1,3,4-oxadiazoles, are present in compounds bearing antimicrobial,⁷⁻⁸

*Corresponding author. Tel: +1-612-625-8687; fax: +1-612-625-4749; daharki@umn.edu.

Supplementary Material: Supplementary data (experimental procedures and NMR spectra) associated with this article can be found online at XXXXX.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

antifungal,⁹ anxiolytic,¹⁰ antidepressant,¹¹ antiproliferative,¹²⁻¹⁷ hypoglycemic,¹⁸ and antiviral activities. Raltegravir, an FDA-approved HIV-1 integrase inhibitor, incorporates a 1,3,4-oxadiazole. However, [1,2,4]triazolo[3,4-*b*][1,3,4]oxadiazoles (**1**) are surprisingly under-investigated. In the few assays executed, compounds containing this moiety exhibited antibacterial activity similar to that of streptomycin,¹⁹ herbicidal activity comparable to the commercially available 2,4-dichlorophenoxyacetic acid (2,4-D), and fungicidal activity akin to the commercial Dithane M-45.²⁰ Furthermore, in a library of oxadiazole derivatives screened for antimicrobial activity, the triazolo-oxadiazole was considered the most active.²¹

The [1,2,4]triazolo[3,4-*b*][1,3,4]oxadiazole heterocycle, **1**, was first suggested in 1961;²² and since then, multiple synthetic approaches have been reported (Figure 1A). In nearly all approaches to **1** the oxadiazole is first prepared and the triazole is formed in the final step. For instance, 1,3,4-oxadiazoles functionalized at the 2-position with acylhydrazines (**2**),^{19,23-25} hydrazones (**3**),²⁶⁻²⁷ and unsubstituted hydrazines (**4**)^{20,28-29} can be directly converted to **1** via triazole cyclization. The triazole has also been formed by reacting hydrazine hydrate with either EtOH and amino oxadiazoles (**5**),²¹ *N*-substituted oxadiazolines (**6**),³⁰ or *N*-acylated oxadiazolones (**7**).³¹ Butler et al. found that hydrazonyl bromides (**8**) could be cyclized via nucleophilic attack of the oxadiazole.³² Bypassing the formation of **8**, Scott et al. found that tribromo-diazobutadienes (**9**) could afford **1** when refluxed with benzhydrazine and Et₃N.³³ Conversely, only two reports of [1,2,4]triazolo[3,4-*b*][1,3,4]oxadiazole formation via late-stage generation of the oxadiazole ring have been reported. Tsuge et al. observed the formation of **1** when carbamoyl chloride (**10**) was treated with anhydrous sodium azide, and proposed the reaction proceeded via a triazolone intermediate able to react with a second equivalent of **10**.³⁴ They, along with Milcent et al., also formed **1** from a pre-functionalized triazole (**11**) using Na₂CO₃³⁴ or POCl₃,³⁵ respectively. Herein, we report a rapid, microwave accelerated synthesis of **1** from readily synthesized 4-acylamino-1,2,4-triazoles (**12**) that are iodinated *in situ* (Figure 1b).

In an effort to synthesize reversible covalent inhibitors of APOBEC3 DNA cytosine-to-uracil deaminases, we discovered the [1,2,4]triazolo[3,4-*b*][1,3,4]oxadiazole synthesis presented herein. In previous studies by our laboratory, we found that substituted 4-amino-1,2,4-triazole-3-thiols inhibit APOBEC3G (A3G) DNA cytosine-to-uracil deaminase activity by covalently engaging A3G Cys321, a critical residue proximal to the active site.³⁶ As thiols are inherently reactive functional groups, we sought to replace this moiety on our inhibitor with a nitrile, compound **15**, to achieve a more drug-like scaffold with tuneable reactivity. The nitrile functional group has gained significant attention as an electrophile for reversible covalent inhibition of therapeutic targets due to its weak reactivity with nucleophiles in solution. For instance, when appropriately positioned in an enzyme, a nitrile can undergo nucleophilic attack from a cysteine residue, forming a transient thioimide adduct that is stabilized by hydrogen bonding with the enzyme.³⁷

Accordingly, we acylated the commercially available 4-amino-4*H*-1,2,4-triazole (**13**) with benzoyl chloride, then attempted direct triazole cyanation of the resulting amide **14**. Direct heterocycle cyanation conditions with CuCN, NaCN, I₂, *t*BuOLi, and 1,10-phenanthroline in *m*-xylene and 1,4-dioxane at 110 °C have been reported³⁸ and similar conditions were attempted with our system. However, the presence of the pendant amide carbonyl instead

promoted cyclization into the triazole to yield the [1,2,4]triazolo[3,4-*b*][1,3,4]oxadiazole **16**, as opposed to target compound **15** (Scheme 1). Given the synthetic ease of elaborating a simple triazole, such as **13**, into a substituted triazolo-oxadiazole such as **16**, especially in comparison to other methods that require more transformations (see Figure 1), we instead turned our attention to optimizing this reaction and examining its mechanism.

Results and Discussion

Our initial efforts focused on determining which reagents were necessary to promote cyclization of **14** to **16** based on the direct cyanation conditions published by Do and Daugulis.³⁸ Systematic removal of the various reaction components revealed that neither 1,10-phenanthroline nor NaCN were necessary to achieve **16** (Table 1). However, when I₂ was omitted, no cyclization occurred and only the amide starting material was recovered. Because starting material solubility was poor when dioxane and xylene were used as co-solvents, both DMF and methanol were also utilized to enhance solubility. However, despite the fact that a homogenous solution was obtained in both instances, these solvent changes appeared to have little effect on the transformation. Finally, it appeared that elevated temperatures (125 °C) were required for the transformation, as I₂, CuCN, and *t*BuOLi were unable to confer **16** at 50 °C, and only amide starting material was recovered under these conditions. At this juncture, we envisioned possible metal-catalyzed cross-couplings or S_NAr intramolecular cyclizations to yield **16**, and devised a series of experiments to probe the reaction mechanism (Table 2).

Our previous studies suggested that **16** may result from a Cu^I-catalyzed cross coupling between the benzamide oxygen and the 3-position of the triazole, either via an iodinated intermediate or C-H activation. To determine if other metal catalysts could afford **16**, we screened Pd(OAc)₂, Pd(PPh₃)₄, and Pd(PPh₃)₂Cl₂ under identical conditions as that used for CuCN. However, little-to-no **16** was observed. Recently, the synthesis of 2-arylbenzoxazoles through oxidative C-O coupling with Cu(OTf)₂ under an O₂ atmosphere has been reported,³⁹ which lead us to evaluate if similar conditions can be employed to deliver **16** from **14** using either CuCN or Cu(OTf)₂ as catalysts. In both instances no increase in yield was observed for the transformation of **14** to **16**, and the condition in which I₂ was omitted, Cu(OTf)₂ as catalyst, resulted in no product formation. Additionally, a similar iodine-mediated oxadiazole formation using Oxone, NaOH, and I₂ has been reported;⁴⁰ however, no cyclization occurred when these published conditions were applied to our system. We further found that nucleophilic iodine sources (e.g., KI) were insufficient to promote cyclization, whereas electrophilic iodine sources (e.g., I₂) resulted in product formation. These results, taken with the fact that cyclization was also observed when only *t*BuOLi and I₂ were utilized (Table 2), suggested a mechanism alternative to metal-catalyzed cross-coupling, and inspired us to investigate I₂-mediated intramolecular cyclization.

In an attempt to explore a step-wise synthesis of **16** – iodination followed by cyclization – we aimed to synthesize the mono-iodinated **17** using previously reported conditions.⁴¹ To our surprise, subjecting **14** to *N*-iodosuccinimide (NIS) in THF at 70 °C not only resulted in the target molecule **17** (Scheme 2a), but was also sufficient to promote cyclization to **16**. Replacing THF with MeCN as solvent increased the solubility of **14**, and together with an

increased microwave temperature of 125 °C, conferred **16** in a 29% isolated yield. Importantly, **17** was not observed at these higher temperatures.

To probe the mechanism of the cyclization, purified **17** was simply dissolved in MeCN and subjected to microwave irradiation at 125 °C. **16** was isolated from this reaction mixture in 32-35% yield (Scheme 2). These results led us to propose the following mechanism: NIS or I₂ mediates the formation of iodinated intermediate **17**, which undergoes intramolecular cyclization through the amide oxygen via a S_NAr mechanism to form **16**. Our data suggests that microwave irradiation at 70 °C is sufficient for iodination to occur, but higher temperatures (125 °C) are required for **17** to cyclize completely to **16**. It is also possible that a second mechanism involving an iodonium species across the C-N double bond of **14** followed by cyclization and elimination of HI is involved in the formation of **16**; however, no experimental evidence has yet been found to support this pathway.

Interestingly, the addition of base (*t*BuOLi) to the NIS-mediated reaction did not enhance the formation of the cyclized product (Table 3), suggesting that succinimide, ambient water, or the iodide anion released after substitution is sufficiently basic for proton abstraction and re-aromatization. Additionally, **14** heated at reflux overnight in MeCN using conventional heating methods (i.e. an oil bath) did allow for cyclization to **16** to occur, but in much lower yield (~9% isolated yield) compared to optimized microwave conditions (29% yield) that require only 10 min reaction times.

One explanation for the modest yield is the observation and isolation of the iodinated byproduct **18** with *m/z* = 312.9579 (calc'd = 312.9581, Figure 2). To push the reaction towards completion while avoiding over-iodination, we screened various equivalents of NIS, as well as varying reaction times and temperatures; however, of the conditions tested, none resulted in a significant improvement in yield (Table 3). Because both the byproduct **18** and starting material **14** could be isolated from the reaction mixture during optimization studies, this competing reaction, namely the formation of **18**, likely plays a role in low reaction yield. When the reaction mixture was treated with excess (4 eq.) of NIS, for instance, all starting material was consumed; however, recovery of the desired product **16** declined (18% yield) as the formation of the iodinated product **18** was promoted (37% yield). We found that 1.1 equivalents of NIS in MeCN heated to 125 °C for 10 min using microwave irradiation conferred the best yield of **16** (29% yield).

This limitation in transformation efficiency can be corrected by blocking the site of additional iodination by employing mono-substituted triazoles (e.g., 3-methyl; **19**) as starting materials. Acylation of **19** to amide **20**, followed by treatment with an excess (4.0 equiv.) of NIS under our established microwave conditions results in formation of **21** in reasonable yields (49-60%; Scheme 3). The substituted [1,2,4]triazolo[3,4-*b*] [1,3,4]oxadiazole **21** was synthesized from the triazole **19** in a 30-43% yield over two steps.

Conclusions

In conclusion, we report a rapid, microwave accelerated method for the synthesis of [1,2,4]triazolo[3,4-*b*][1,3,4]-oxadiazoles from readily available commercial building blocks.

This method, despite modest yields, offers an alternative approach for synthesizing this interesting heterocycle in only two synthetic steps. We believe our method expands the synthetic accessibility of this heterocycle, which may enable its evaluation for a variety of biological applications.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We gratefully acknowledge funding by the National Institutes of Health (R01-GM110129) and the University of Minnesota, Office of the Vice President for Research (Equipment Grant-in-Aid to purchase the CEM Discover SP Microwave Synthesizer). S.L.B. thanks the University of Minnesota, Undergraduate Research Opportunities Program (UROP) and the Department of Chemistry Heisig/Gleysteen Summer Undergraduate Research Fellowship Program for financial support. M.E.O. acknowledges the National Institutes of Health for a Ruth L. Kirschstein NRSA Predoctoral Fellowship (F31-CA18324). Mass spectrometry was performed at the Analytical Biochemistry Core Facility of the Masonic Cancer Center (University of Minnesota), which is supported in part by the National Institutes of Health (P30-CA77598).

References

1. Holla BS, Gonsalves R, Shenoy S. *Farmaco*. 1998; 53:574–578. [PubMed: 10081820]
2. Turan-Zitouni G, Kaplancıklı ZA, Yıldız MT, Chevallet P, Kaya D. *Eur J Med Chem*. 2005; 40:607–613. [PubMed: 15922844]
3. Walczak K, Gondela A, Suwi ski J. *Eur J Med Chem*. 2004; 39:849–853. [PubMed: 15464618]
4. Holla BS, Veerendra B, Shivananda MK, Poojary B. *Eur J Med Chem*. 2003; 38:759–767. [PubMed: 12932907]
5. Amir M, Shikha K. *Eur J Med Chem*. 2004; 39:535–545. [PubMed: 15183912]
6. Almasirad A, Tabatabai SA, Faizi M, Kebriaeezadeh A, Mehrabi N, Dalvandi A, Shafiee A. *Bioorg Med Chem Lett*. 2004; 14:6057–6059. [PubMed: 15546729]
7. Ahsan MJ, Samy JG, Khalilullah H, Nomani MS, Saraswat P, Gaur R, Singh A. *Bioorg Med Chem Lett*. 2011; 21:7246–7250. [PubMed: 22071303]
8. ahin G, Palaska E, Ekizo lu M, Özalp M. *Farmaco*. 2002; 57:539–542. [PubMed: 12164209]
9. Liu F, Luo XQ, Song BA, Bhadury PS, Yang S, Jin LH, Xue W, Hu DY. *Bioorg Med Chem*. 2008; 16:3632–3640. [PubMed: 18329885]
10. Harfenist M, Heuser DJ, Joyner CT, Batchelor JF, White HL. *J Med Chem*. 1996; 39:1857–1863. [PubMed: 8627609]
11. Ergün Y, Orhan ÖF, Özer UG, Gi i G. *Eur J Pharmacol*. 2010; 630:74–78. [PubMed: 20035741]
12. Jin L, Chen J, Song B, Chen Z, Yang S, Li Q, Hu D, Xu R. *Bioorg Med Chem Lett*. 2006; 16:5036–5040. [PubMed: 16876405]
13. Abadi AH, Eissa AAH, Hassan GS. *Chem Pharm Bull*. 2003; 51:838–844. [PubMed: 12843591]
14. Bajaj S, Asati V, Singh J, Roy PP. *Eur J Med Chem*. 2015; 97:124–141. [PubMed: 25965776]
15. Du QR, Li DD, Pi YZ, Li JR, Sun J, Fang F, Zhong WQ, Gong HB, Zhu HL. *Bioorg Med Chem*. 2013; 21:2286–2297. [PubMed: 23490159]
16. Shahzad SA, Yar M, Bajda M, Jadoon B, Khan ZA, Naqvi SAR, Shaikh AJ, Hayat K, Mahmmod A, Mahmood N, Filipek S. *Bioorg Med Chem*. 2014; 22:1008–1015. [PubMed: 24411198]
17. Zheng QZ, Zhang XM, Xu Y, Cheng K, Jiao QC, Zhu HL. *Bioorg Med Chem*. 2010; 18:7836–7841. [PubMed: 20947362]
18. Shingalapuri RV, Hosamani KM, Keri RS, Hugar MH. *Eur J Med Chem*. 2010; 45:1753–1759. [PubMed: 20122763]
19. Sanjeeva Reddy C, Vani Devi M, Rajesh Kumar G, Sunitha M, Nagaraj A. *J Heterocyclic Chem*. 2013; 50:557–562.

20. Singh H, Yadav LDS, Bhattacharya BK. Indian J Chem, Sect B. 1979; 17B:499–501.
21. Gad El-Karim IA, Amine MS, Mahmoud AA, Gouda AS. J Surfactants Deterg. 2014; 17:509–523.
22. Potts KT. Chem Rev. 1961; 61:87–127.
23. EL-Saraf GA, EL-Sayed AM. Synth Commun. 1996; 26:3827–3839.
24. Feng XM, He X, Jiang YZ. Gaodeng Xuexiao Huaxue Xuebao. 1998; 19:577–579.
25. Qiu ZZ, Dai CF, Chao SJ, Xu PF, Zhang ZY. J Chin Chem Soc. 2004; 51:1343–1346.
26. Abdel-Aal MT, El-Sayed WA, El-Kosy SM, El-Ashry ESH. Arch Pharm Chem Life Sci. 2008; 341:307–313.
27. Vakula TR, Srinivasan VR. Indian J Chem. 1971; 9:901–903.
28. El-Dean AMK. J Chem Res Miniprint. 1996:1401–1415.
29. Moustafa OS, Badr MZA, El-Emary TI. Bull Korean Chem Soc. 2002; 23:567–570.
30. Aly AS, Fahmy AA, Zaki MEA, Abdel-Megeid FME. Egypt J Pharm Sci. 1992; 33:699–711.
31. Gogoi PC, Katakya JCS. Heterocycles. 1991; 32:237–244.
32. Butler RN, Lambe TM, Scott FL. J Chem Soc, Perkin Trans. 1972; 1:269–273.
33. Scott FL, Lambe TM, Butler RN. Tetrahedron Lett. 1971; 12:1729–1732.
34. Tsuge O, Yoshida M, Kanemasa S. J Org Chem. 1974; 39:1226–1228.
35. Milcent R, Redeuilh C. J Heterocyclic Chem. 1980; 17:1691–1696.
36. Olson ME, Li M, Harris RS, Harki DA. ChemMedChem. 2013; 8:112–117. [PubMed: 23180603]
37. Frizler M, Stirnberg M, Sisay MT, Gutschow M. Curr Top Med Chem. 2010; 10:294–322. [PubMed: 20166952]
38. Do HQ, Daugulis O. Org Lett. 2010; 12:2517–2519. [PubMed: 20441204]
39. Ueda S, Nagasawa H. Angew Chem Int Ed. 2008; 47:6411–6413.
40. Shinde VN, Ugarkar BG, Ghorpade SR. J Chem Res. 2013; 37:53–54.
41. Katkevica S, Salun P, Jirgensons A. Tetrahedron Lett. 2013; 54:4524–4525.

Highlights

- [1,2,4]triazolo[3,4-*b*][1,3,4]oxadiazoles were synthesized in two steps
- 10-min microwave-accelerated cyclization forms the oxadiazole ring
- 3-substituted 1,2,4-triazoles cyclize in higher yields without byproduct formation

Figure 1.

(A) Previously reported methods for the preparation of heterocycles represented by **1**. (B) Our strategy for the synthesis of **1** from readily accessible precursors, such as **12**.

Figure 2.
Isolated byproduct **18** (yields are shown in Table 3).

Scheme 1.

Attempted synthesis of nitrile **15** via **14** under previously published conditions³⁸ for direct cyanation of heterocycles and isolated **16**. (a) Benzoyl chloride, 1,4-dioxane, reflux, 24 h, 60-79% (b) CuCN (0.7 equiv.), NaCN (1.2 equiv.), I₂ (1.5 equiv.), *t*BuOLi (1.2 equiv.), 1,10-phenanthroline (1.0 equiv.), *m*-xylene, 1,4-dioxane, MW 125 °C, 18%.

Scheme 2.

Two-step synthesis of **16** leads to a proposed mechanism of [1,2,4]triazolo[3,4-*b*] [1,3,4]oxadiazole formation via **17**. (a) NIS, MeCN, MW, 70 °C, 20 min, 36%. (b) MeCN, MW, 125 °C, 10 min, 32-35%. (c) NIS, MeCN, MW, 125 °C, 10 min, 29%

Scheme 3.

Synthesis and subsequent cyclization of the 3-methyl analogue **20**. (a) benzoyl chloride, 1,4-dioxane, reflux, 24 h, 61-72%. (b) NIS, MeCN, MW 125 °C, 10 min, 49-60%.

Table 1

Initial studies to determine necessary reagents for conversion of **14** to **16** based on previously reported³⁸ direct cyanation conditions.^{a,b}

Reagents	Solvent(s)	Temp (°C)	Time (min)	% Yield ^c
CuCN, <i>t</i> BuOLi, I ₂ , NaCN, Phenanthroline	1,4-dioxane/ <i>m</i> -xylene	125	30	18
CuCN, <i>t</i> BuOLi, I ₂	1,4-dioxane/ <i>m</i> -xylene	125	30	12
CuCN, <i>t</i> BuOLi	1,4-dioxane/ <i>m</i> -xylene	125	30	N/A ^d
CuCN, <i>t</i> BuOLi, I ₂	1,4-dioxane/ <i>m</i> -xylene	125	5	13
CuCN, <i>t</i> BuOLi, I ₂	DMF	125	30	16
CuCN, <i>t</i> BuOLi, I ₂	MeOH	125	30	12
CuCN, <i>t</i> BuOLi, I ₂	MeOH	50	30	N/A

^aReactions were typically performed on 0.4 mmol scale (for **14**)

^bMicrowave conditions, 200 W maximum

^cIsolated yields

^dN/A = No product observed

Table 2

Alternative conditions to assess conversion of **14** to **16**.^a

Reagents	Solvent(s)	Heat Source ^b	Temp (°C)	Time	% Yield ^c
Pd(OAc) ₂ , I ₂ , <i>t</i> BuOLi	DMF	MW	125	30 min	4
Pd(PPh ₃) ₄ , I ₂ , <i>t</i> BuOLi	1,4-dioxane/ <i>m</i> -xylene	MW	125	30 min	N/A ^d
Pd(PPh ₃) ₂ Cl ₂ , I ₂ , <i>t</i> BuOLi	MeOH	MW	125	30 min	1
CuCN, I ₂ , <i>t</i> BuOLi, O ₂ (1 atm)	DMF	Oil bath	125	23 h	9
Cu(OTf) ₂ , O ₂ (1 atm)	<i>o</i> -xylene	Oil bath	140	40 h	N/A
Oxone, I ₂ , NaOH	MeOH	-	r.t.	43 h	N/A
CuCN, KI, <i>t</i> BuOLi	1,4-dioxane/ <i>m</i> -xylene	MW	125	30 min	N/A
<i>t</i> BuOLi, I ₂	MeCN	MW	125	10 min	11

^aReactions were typically performed on 0.4 mmol scale (for **14**)^bMW = Microwave heating, 200 W maximum. Oil bath = conventional heating.^cIsolated yields^dN/A = No

Table 3Optimization of NIS-mediated cyclization of **14** to **16**.^{a,b}

Reagent(s)	Temp. (°C)	Time (min)	% Yield ^c (16)	% Yield ^c (18)	% Recovered ^c (14)
NIS (1.0 eq.), tBuOLi (1.2 eq.) ^d	125	10	13	1	66
NIS (0.9 eq.)	125	10	23	0	34
NIS (1.0 eq.) ^e	125	10	25	0	26
NIS (1.1 eq.)	125	10	29	7	18
NIS (1.2 eq.)	125	10	18	1	11
NIS (1.3 eq.)	125	10	22	9	31
NIS (2.0 eq.)	125	10	22	25	2
NIS (4.0 eq.)	125	10	18	37	0
NIS (1.0 eq.)	125	30	9	1	24
NIS (1.0 eq.) ^d	95	10	19	1	34
NIS (1.0 eq.) ^d	140	10	27	1	10

^aReactions were typically performed on 0.4 mmol scale (for **14**)^bMicrowave conditions, 200 W maximum. Performed in duplicate in MeCN. Mean yields are shown.^cIsolated yields^dSingle measurement^eTriplicate measurements